Antiinfective medicine sales in Germany are forecasted to grow steadily over the next five years, starting from a value of 39.1 USD per capita in 2024 and increasing to 41.4 USD per capita by 2028. The consistent year-on-year growth suggests a relatively stable market. From 2024 to 2025, the growth rate is 1.53%, and from 2025 to 2026, it is again 1.51%. The compound annual growth rate (CAGR) over the five-year period from 2024 to 2028 is approximately 1.44%.
Future trends to watch for include potential impacts of healthcare policy changes, advancements in medical technology, and demographic shifts that could affect market dynamics and demand for antiinfective medicines in Germany. Additionally, emerging threats from antibiotic resistance could drive innovation and influence sales.
